Diagnosis of Bipolar I or Bipolar II Disorder, according to DSM-5 criteria.
Currently in a depressive, manic, hypomanic, mixed, or euthymic phase, as defined by DSM-5 and clinical evaluation.
No use of psychotropic medications during the 12 months preceding enrollment, except for low-dose benzodiazepines or antipsychotics used intermittently to manage sleep disturbances or anxiety symptoms.
No prior treatment with lithium at any point in the patient's psychiatric history.
Medically stable and deemed suitable for study participation.
Ability and willingness to provide written informed consent before any study procedure For the Human Healthy Control group
participants aged 18-65 years will be included, while subjects with DSM-5 disorders or a family history of psychiatric disorders will be excluded.
You may not be if
Current or past diagnosis of schizophrenia, schizoaffective disorder, or borderline personality disorder as the primary psychiatric condition.
Diagnosis of moderate to severe substance use disorder (excluding nicotine) within the past 12 months.
Active suicidal ideation with plan or intent
History of major neurological disorders, including epilepsy, traumatic brain injury, or neurodegenerative disease.
Previous exposure to lithium at any point in the individual's psychiatric history.
Use of psychotropic medication within the 12 months before enrollment.
Presence of uncontrolled or clinically significant medical conditions, including but not limited to severe hepatic, renal, or cardiovascular disease.
Clareo Health | Testing a New Gold Nanoparticle-Based Lithium Delivery Method for Bipolar Disorder in Laboratory Models
